TVARDI THERAPEUTICS, INC. Available-for-sale Securities, Gross Realized Gain (Loss)
TVARDI THERAPEUTICS, INC. (TVRD) reported Available-for-sale Securities, Gross Realized Gain (Loss) of -$15.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-07.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2018-08-07
- TVARDI THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-06-30 was $0.00.
- TVARDI THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-03-31 was -$15.00K, a 600.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-12-31 was $1.00K, a 90.91% decline year-over-year.
- TVARDI THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-09-30 was $1.00K.
- TVARDI THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $5.00K, a 78.26% decline from fiscal 2016.
- TVARDI THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $23.00K.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$15.00K 10-Q · filed 2018-08-07 | -$14.00K derived: sum of 3 quarters · filed 2018-08-07 | -$13.00K derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | -$15.00K 10-Q · filed 2018-05-09 | -$14.00K derived: sum of 2 quarters · filed 2018-05-09 | -$13.00K derived: sum of 3 quarters · filed 2018-05-09 | -$13.00K derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $2.00K derived: sum of 2 quarters · filed 2018-03-15 | $2.00K derived: sum of 3 quarters · filed 2018-08-07 | $5.00K 10-K · filed 2018-03-15 |
| 2017-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $1.00K derived: sum of 2 quarters · filed 2018-08-07 | $4.00K 10-Q · filed 2017-11-02 | $15.00K derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $3.00K 10-Q · filed 2018-08-07 | $14.00K derived: sum of 3 quarters · filed 2018-08-07 | |
| 2017-03-31 | $3.00K 10-Q · filed 2018-05-09 | $14.00K derived: sum of 2 quarters · filed 2018-05-09 | ||
| 2016-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $23.00K 10-K · filed 2018-03-15 | ||
| 2016-09-30 | $12.00K 10-Q · filed 2017-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |